SBIR/STTR Research Award
Evaluation of TRB-N0224, a Proprietary Chemically-Modified Curumin, for the Treat
Award amount
$223,797Program and phase
STTR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- TRAVERSE BIOSCIENCES, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- SRV7TZCMJCE4
- Solicitation number
- PA13-235
- Topic code
- NIA
Research abstract
DESCRIPTION (provided by applicant): Traverse Biosciences Inc. is a pre-clinical stage drug development company working to commercialize new chemical entities which act to resolve inflammatory conditions through pleiotropic host-modulation of pathologically unrestrained matrix metalloproteinases (MMPs) and pro-inflammatory cytokines. The company's lead drug candidate, TRB-N0224, is a proprietary chemically modified curcumin developed by the co-inventor of Periostat(R) and Oracea(R), currently the only FDA-approved MMP inhibitors. Osteoarthritis [OA] is the most common form of joint disease and a leading cause of disability in the elderly. OA currently affects 27M Americans, and it is characterized by progressive destruction of the articular cartilage and loss of its extracellular matrix. Current treatments for OA involve pain relief and anti-inflammatory compounds to increase tolerance for daily activities. However, available therapies are primarily palliative, have low efficacy and fail to prevent pro
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Pre Clinical Safety and Efficacy of TRB N for the Treatment of Periodontal Disease
- Evaluation of TRB-N0224, a Proprietary Chemically Modified Curcumin, for the Treatment of Periodontal Disease in a LPS-Induced Rat Model
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Evaluate the Safety, Tolerability, and Immunogenicity of Adjuvanted Preventive Dual Aβ/tau Vaccine, Duvax in Healthy Volunteers
- A Drug Discovery Platform to Prioritize Development of Natural Product Neuromodulators for Treating Cognitive Impairment
- VR-CARES: Feasibility of Virtual Reality for Caregiver Assembly, Relief, Empowerment, and Support to improve social connection, health, and at-home dementia care
- Developing an Integrated Brain State Monitor for Personalized Anesthesia Decision Support: Preventing Postoperative Delirium in Elderly and Patients At Risk for Alzheimer's or Related Dementias
- Lead Optimization of a Therapeutic Candidate for Alzheimer’s Disease
Research funding history
3 SBIR/STTR records share this UEI (2014–2016). Reported award amounts total $1,749,938. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services